EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database

Gu-Shun Lai iD, Jian-Ri Li, Shian-Shiang Wang, Chuan-Shu Chen, Chun-Kuang Yang, Chia-Yen Lin, Sheng-Chun Hung, Kun-Yuan Chiu, Shun-Fa Yang

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0299102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Gu-Shun Lai und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The role of upfront cytoreductive nephrectomy remains debatable in the present era of tyrosine kinase inhibitors and immune checkpoint inhibitors. Here, we aimed to evaluate the outcomes of metastatic renal cell carcinoma patients treated with upfront CN and modern systemic therapies.

Methods

Using the TriNetX network database, we identified patients, in the period from 2008 to 2022, who were diagnosed with metastatic renal cell carcinoma, receiving first-line systemic therapies with tyrosine kinase inhibitors or immune checkpoint inhibitors. Their overall survivals were evaluated using the Kaplan-Meier method as well as multivariable regressions.

Results

We identified 11,094 patients with metastatic renal cell carcinoma. Of them, 2,914 (43%) patients in the tyrosine kinase inhibitor cohort (n = 6,779), and 1,884 (43.7%) in the immune checkpoint inhibitors cohort (n = 4315) underwent upfront cytoreductive nephrectomy. Those receiving upfront cytoreductive nephrectomy showed survival advantages with either tyrosine kinase inhibitor (Hazard ratio 0.722, 95% Confidence interval 0.67–0.73, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsHumansTyrosine Kinase InhibitorsCytoreduction Surgical ProceduresImmune Checkpoint InhibitorsProtein Kinase InhibitorsNephrectomyRetrospective Studies

Substanzen

Tyrosine Kinase InhibitorsImmune Checkpoint InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
  • Department of Surgery, Division of Urology, Taichung Veterans General Hospital, Taichung, Tawan.
  • Department of Medicine and Nursing, Hungkuang University, Taichung, Taiwan.
  • Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan.
  • Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.

ORCID-Profile: Gu-Shun Lai

Zitieren

APA

Lai, G. S., Li, J. R., Wang, S. S., Chen, C. S., Yang, C. K., Lin, C. Y., Hung, S. C., Chiu, K. Y., & Yang, S. F. (2024). Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database. PLOS ONE. https://doi.org/10.1371/journal.pone.0299102

Vancouver

Lai GS, Li JR, Wang SS, Chen CS, Yang CK, Lin CY, et al. Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database. PLOS ONE. 2024. doi:10.1371/journal.pone.0299102

BibTeX
@article{Lai2024,
  author = {Lai, Gu-Shun and Li, Jian-Ri and Wang, Shian-Shiang and Chen, Chuan-Shu and Yang, Chun-Kuang and Lin, Chia-Yen and Hung, Sheng-Chun and Chiu, Kun-Yuan and Yang, Shun-Fa},
  title = {Outcome benefits of upfront cytoreductive nephrectomy for patients with metastatic renal cell carcinoma: An analysis of the TriNetX database},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0299102}
}
Kostenlos starten →